Cargando…
Cardiovascular outcomes of β‐blocker—calcium channel blocker initial dual therapy vs. other initial dual therapies in Chinese patients with hypertension: A real‐world retrospective study
This retrospective study compared cardiovascular (CV) outcomes between initial β‐blocker (BB) + calcium channel blocker (CCB) dual therapy (“B + C”) and other initial dual therapies in Chinese newly diagnosed hypertensive patients. In this study, all patients in a regional electronic database with n...
Autores principales: | Lin, Junxiong, Guo, Qinghui, Lu, Zhuoqiang, Chai, Dajun, Peng, Feng, Lin, Jinxiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184485/ https://www.ncbi.nlm.nih.gov/pubmed/37120711 http://dx.doi.org/10.1111/jch.14665 |
Ejemplares similares
-
Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension
por: Sung, Ki‐Chul, et al.
Publicado: (2023) -
Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
por: Jin, Xuan, et al.
Publicado: (2020) -
Age‐specific differences in hypertension combination management and associated factors influencing treatment choice
por: Xiong, Jianfei, et al.
Publicado: (2023) -
Calcium-Channel Blockers: An Alternative Therapy to Beta-Blockers for Myocardial Infarction?
por: Hao, Kiyotaka, et al.
Publicado: (2023) -
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)